CA
NZ
UK
AU
IND
US
…
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Halozyme Therapeutics develops enzyme-based technology to enable subcutaneous delivery of biologic drugs and advance its own therapeutic programs. Long-term growth may be driven by licensing royalties and milestones from partners, broader adoption of subcutaneous formulations and pipeline progress. Investors may find the company attractive for recurring partner-derived revenue and platform leverage across multiple candidates.
Principal risks include reliance on a small number of partner programs for revenue, clinical and regulatory uncertainty for proprietary candidates, competition from alternative delivery technologies, and potential intellectual property or execution setbacks investors should monitor.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 466.88M | 557.13M | 348.33M | 248.92M | 248.52M |
| Net income | 316.89M | 444.09M | 281.59M | 202.13M | 402.71M |
| Selling general administrative | 207.09M | 154.34M | 149.18M | 143.53M | 50.32M |
| Gross profit | 1091.17M | 855.91M | 636.89M | 520.81M | 361.90M |
| Reconciled depreciation | 88.05M | 81.31M | 84.86M | 49.64M | 3.00M |
| Ebit | 816.29M | 575.23M | 367.09M | 267.53M | 272.90M |
| Ebitda | 904.34M | 656.54M | 451.95M | 310.68M | 275.90M |
| Depreciation and amortization | 88.05M | 81.31M | 84.86M | 43.15M | 3.00M |
| Non operating income net other | - | - | - | -1.67M | -19.86M |
| Operating income | 816.29M | 551.48M | 337.57M | 267.53M | 275.90M |
| Other operating expenses | 580.32M | 463.85M | 491.68M | 392.58M | 167.41M |
| Interest expense | 18.13M | 18.09M | 18.76M | 16.95M | 7.53M |
| Tax provision | 149.99M | 113.04M | 66.73M | 46.79M | -154.19M |
| Net interest income | -18.13M | -18.09M | -18.76M | -16.95M | -7.53M |
| Income tax expense | 149.99M | 113.04M | 66.73M | 46.79M | -154.19M |
| Total revenue | 1396.61M | 1015.32M | 829.25M | 660.12M | 443.31M |
| Total operating expenses | 274.88M | 304.43M | 299.32M | 253.28M | 86.00M |
| Cost of revenue | 305.44M | 159.42M | 192.36M | 139.30M | 81.41M |
| Total other income expense net | -349.42M | 5.66M | 10.76M | -18.61M | -27.38M |
| Net income from continuing ops | 316.89M | 444.09M | 281.59M | 202.13M | 402.71M |
| Net income applicable to common shares | - | - | - | 202.13M | 402.71M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2525.32M | 2063.48M | 1733.27M | 1841.51M | 1104.43M |
| Intangible assets | 981.47M | 401.83M | 472.88M | 546.65M | - |
| Other current assets | 64.64M | 38.95M | 48.61M | 45.02M | 40.48M |
| Total liab | 2476.51M | 1699.66M | 1649.46M | 1671.71M | 907.48M |
| Total stockholder equity | 48.81M | 363.82M | 83.81M | 169.80M | 196.95M |
| Other current liab | 156.19M | 128.85M | 100.68M | 96.52M | 24.44M |
| Common stock | 0.12M | 0.12M | 0.13M | 0.14M | 0.14M |
| Capital stock | 0.12M | 0.12M | 0.13M | 0.14M | 0.14M |
| Retained earnings | 54.79M | 359.87M | 90.55M | 143.22M | -58.91M |
| Other liab | - | - | - | 17.73M | 3.07M |
| Good will | 580.36M | 416.82M | 416.82M | 409.05M | - |
| Other assets | - | - | - | 71.23M | 169.35M |
| Cash | 133.82M | 115.85M | 118.37M | 234.19M | 118.72M |
| Total current liabilities | 177.09M | 139.10M | 112.49M | 130.79M | 117.15M |
| Current deferred revenue | - | - | -32.20M | 3.25M | 1.75M |
| Net debt | -133.82M | 1389.95M | 1380.88M | 1271.90M | 757.96M |
| Short term debt | - | - | 32.20M | 13.33M | 89.42M |
| Short long term debt | - | - | - | 13.33M | 89.42M |
| Short long term debt total | - | 1505.80M | 1499.25M | 1506.10M | 876.67M |
| Other stockholder equity | 12.00M | - | 2.41M | 27.37M | 256.35M |
| Property plant equipment | - | - | - | 75.57M | 8.79M |
| Total current assets | 825.21M | 1085.34M | 746.42M | 739.01M | 926.29M |
| Net tangible assets | - | - | - | -783.65M | 196.95M |
| Short term investments | 9.00M | 480.22M | 217.63M | 128.60M | 622.20M |
| Net receivables | 441.27M | 308.45M | 234.21M | 231.07M | 90.97M |
| Long term debt | 2142.63M | 1505.80M | 1499.25M | 1492.77M | 787.25M |
| Inventory | 176.47M | 141.86M | 127.60M | 100.12M | 53.91M |
| Accounts payable | 20.90M | 10.25M | 11.82M | 17.69M | 1.54M |
| Accumulated other comprehensive income | -18.09M | 3.83M | -9.28M | -0.92M | -0.62M |
| Common stock total equity | - | - | - | 0.14M | 0.14M |
| Retained earnings total equity | - | - | - | 143.22M | -58.91M |
| Non currrent assets other | 56.15M | 80.60M | 17.82M | 26.80M | 13.91M |
| Non current assets total | 1700.12M | 978.14M | 986.85M | 1102.50M | 178.14M |
| Long term debt total | - | - | - | 1492.77M | 787.25M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 474.89M | -262.72M | -96.91M | 490.92M | -404.83M |
| Change to liabilities | - | - | - | 24.54M | 1.17M |
| Total cashflows from investing activities | -545.81M | -262.72M | -96.91M | -487.00M | -406.29M |
| Net borrowings | 451.13M | 0.00M | -13.48M | 617.44M | 415.81M |
| Total cash from financing activities | -85.17M | -218.86M | -407.99M | 362.37M | 77.86M |
| Change to operating activities | - | - | - | -9.06M | -11.55M |
| Net income | 316.89M | 444.09M | 281.59M | 202.13M | 402.71M |
| Change in cash | 20.57M | -2.52M | -116.33M | 115.48M | -28.98M |
| Begin period cash flow | 115.85M | 118.37M | 234.69M | 119.22M | 148.20M |
| End period cash flow | 136.42M | 115.85M | 118.37M | 234.69M | 119.22M |
| Total cash from operating activities | 651.56M | 479.06M | 388.57M | 240.11M | 299.44M |
| Depreciation | 88.05M | 88.66M | 84.86M | 49.64M | 3.00M |
| Other cashflows from investing activities | -287.77M | -252.03M | - | -973.11M | - |
| Dividends paid | - | - | 13.48M | - | -12.54M |
| Change to inventory | 2.55M | -67.38M | -26.88M | -17.48M | 7.37M |
| Change to account receivables | -128.06M | -74.25M | -3.34M | -83.94M | 6.75M |
| Sale purchase of stock | -342.37M | -250.00M | -402.38M | -200.00M | -350.06M |
| Other cashflows from financing activities | -85.17M | 31.14M | 7.88M | 995.78M | 796.99M |
| Change to netincome | - | - | - | 67.02M | -113.65M |
| Capital expenditures | 6.97M | 10.70M | 15.29M | 4.81M | 1.46M |
| Change receivables | - | - | - | -83.94M | 6.75M |
| Cash flows other operating | - | - | - | -10.73M | -13.80M |
| Cash and cash equivalents changes | - | - | - | 115.48M | -28.98M |
| Change in working capital | -152.26M | -136.27M | -38.67M | -85.95M | 3.74M |
| Stock based compensation | 51.56M | 43.38M | 36.62M | 24.40M | 20.82M |
| Other non cash items | 346.68M | 39.20M | -10.33M | 9.89M | 24.61M |
| Free cash flow | 644.59M | 468.37M | 373.28M | 235.30M | 297.98M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HALO Halozyme Therapeutics Inc |
-18.66 15.17% |
104.30 | 31.16 | 10.99 | 7.25 | 85.35 | 8.51 | 19.72 |
| NVO Novo Nordisk A/S |
0.01 0.02% |
40.31 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
4.59 0.85% |
547.09 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
1.45 0.16% |
904.35 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
| Name | Title | Year Born |
|---|---|---|
| Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | Pres, CEO & Director | 1963 |
| Dr. Michael J. LaBarre Ph.D. | Chief Technical Officer | 1964 |
| Ms. Nicole LaBrosse | CFO & Director | 1983 |
| Ms. Tram Bui | VP of Investor Relations & Corp. Communications | NA |
| Mr. Mark Snyder Esq. | Gen. Counsel, Chief Compliance Officer & Corp. Sec. | NA |
| Ms. Amy Marinne Fox | Chief HR Officer | NA |
| Dr. Steve Knowles MBBS | Chief Medical Officer | NA |
| Mr. Todd Butler | Chief of Staff to the CEO, VP & Head of Project Management | NA |
| Dr. Christopher Bryant Ph.D. | Chief Manufacturing Officer & Head of Technical Operations | 1961 |
| Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | President, CEO & Director | 1963 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...